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Abstract: Individuals living in areas with stable transmission of Plasmodium 
falciparum parasites develop substantial protective immunity to the disease 
during childhood. Because of naturally acquired immunity, which appears 
mainly to target parasite-encoded Variable Surface Antigens (VSA) on the 
Infected Erythrocytes (IE), severe and life-threatening disease among adults in 
such areas is rare. However, low-grade asymptomatic parasitaemia continues to 
be present in a large proportion of people. So far, experimental P. falciparum 
malaria vaccination employing non-VSA antigens have resulted in variable 
degrees of protection, including sterile protection, but the duration of the 
protection afforded is short-lived, probably due to insufficient boosting. Based 
on these findings, our approach to vaccine development is to accelerate 
naturally acquired VSA-specific immunity. The ambition is to develop 
vaccines that will protect against mortality and severe morbidity, but which 
allow persistence of low-grade, asymptomatic infection. Hopefully, this 
approach will ensure regular boosting of immunity that appears necessary for 
the long-lasting protection required of vaccines to be deployed in  
malaria-endemic areas. 
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“The road toward a safe and efficient malaria vaccine being available and 




About 40% of the world’s population lives in areas with risk of being infected  
by Plasmodium falciparum parasites, the causative agent of the most severe form  
of malaria affecting humans. Falciparum malaria is estimated to cause 500 million 
clinical cases annually, mostly small children and pregnant women in sub-Saharan 
Africa, and to cost the lives of 1–3 million people. No vaccine suitable for mass 
vaccination is available despite decades of research (Richie and Saul, 2002). In the 
meantime, the malaria problem is growing worse, particularly in sub-Saharan Africa 
where it has always been the worst (Korenromp et al., 2003). This is mainly due to 
increasing problems with drug resistance, insecticide resistance and overwhelmed and 
underfunded health systems in most of the affected countries; problems that until 
recently have failed to attract the international attention they so glaringly deserve.  
Geo-political issues aside, there are two main types of problems with malaria: financial 
and scientific. 
Malaria is a poverty trap. It is both a cause and a consequence of hardship, as has 
been eloquently and convincingly documented elsewhere (Sachs and Malaney, 2002). 
The bottom line is that the vast majority of malaria victims are poor or outright destitute. 
Accordingly, the incentives for pharmaceutical industry involvement in malaria research 
and development are limited, as the prospects for attractive returns on investments appear 
bleak (Ridley, 2002). In its place, a large proportion of the funding for research towards 
the development of new prophylactic and therapeutic interventions traditionally has 
come from military sources. Armed forces have a legitimate interest in protecting their 
personnel deployed in malarious areas – malaria casualties under such circumstances 
often outnumber those from combat – and their ambition is consequently to achieve 
complete protection of personnel in the short term (during deployment), while long-term 
sustainability of protection is of secondary concern. In contrast, for those living 
permanently in endemic areas the achievement of sustainable long-term protection is 
probably more important than solid protection. Encouragingly, there is a growing 
international awareness that the burden of malaria constitutes a major, intolerable 
obstacle to economic development in large parts of the world, and that there is a need to 
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increase funding for both basic and applied research specifically addressing the problem 
of malaria facing people in endemic countries (http://www.rbm.who.int). This research 
includes malaria vaccine development. 
Malaria vaccines have been on the research agenda for several decades. Twenty years 
ago, such vaccines appeared a feasible goal (Wernsdorfer, 1985) – and they still do 
(Targett, 2005). However, progress has been less than breath-taking and despite recent 
accomplishments (e.g. Alonso et al., 2004), truly effective vaccines suitable for mass 
vaccination in endemic countries remain roughly as far away as they were thought to be 
twenty or more years ago (Richie and Saul, 2002; Targett, 2005). Arguably, the main 
obstacle to malaria vaccine development has been – and to some extent continues to  
be – our lack of understanding of how immunity to malaria operates. Too often, antigens 
have been considered important mainly because they are known, and responses 
considered important mostly because they have been measured. Furthermore, 
associations have been often presented as proof of causal relationships. 
At the Centre for Medical Parasitology, we have used as our starting point the fact 
that people living in areas of stable P. falciparum transmission acquire substantial 
protective immunity following years of exposure and repeated disease episodes. 
Protective immunity can therefore be acquired following exposure to P. falciparum 
parasites. We are studying the mechanisms and targets of this immunity with the 
ambition to learn how to accelerate its development through vaccination. The goal is 
vaccines that will provide long-lasting, sustainable protection from mortality and severe 
morbidity associated with specific P. falciparum malaria syndromes, but which allows 
continued presence of parasitemia. Vaccines that are specifically designed for peoples 
living in endemic countries. 
2 The P. falciparum parasites and the disease they cause 
Human infection with P. falciparum parasites begins with the injection of  
sporozoite-stage parasites during the blood meal of an infected Anopheles mosquito. The 
sporozoites rapidly migrate to the liver, where they invade hepatocytes. Once inside a 
liver cell, the parasite undergoes a series of nuclear divisions (known as exoerythrocytic 
or tissue schizogony) over about a week, which result in the formation of as many as 
30,000 merozoites per sporozoite. This part of the infection is clinically silent. 
Eventually, the infected liver cells rupture and release the merozoites into the blood 
stream, where they invade erythrocytes and initiate the asexual multiplication cycle that 
is associated with all clinical symptoms of infection. Upon invasion, each merozoite 
transforms into a ring-stage parasite and after about 18 hr into a trophozoite.  
The trophozoite undergoes several nuclear divisions resulting in the formation of a 
schizont composed of 8–24 merozoites. Forty-eight hours after invasion, the Infected 
Erythrocytes (IE) burst. The released merozoites invade new erythrocytes to continue the 
multiplication cycle. Many of the clinical symptoms of malaria are associated with  
IE rupture, and as infections are often more or less synchronous (all IE bursting at 
approximately the same time), symptoms may increase and decrease in a two-day cycle. 
At some point, some merozoites transform into male or female gametocytes upon 
erythrocyte invasion rather than continuing the asexual multiplication cycle. The 
gametocytes do not divide, and their further development depends on their ingestion by 
an Anopheles mosquito, inside which the parasite life cycle is completed. 
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Only IE younger than about 18 hr are present in the peripheral blood stream. Later 
developmental stages (trophozoites and schizonts) are retained in the vasculature of 
various tissues by means of parasite-encoded adhesion molecules on the IE surface. This 
process, called sequestration, is considered an important mechanism by which the 
parasite avoids recognition and destruction of IE in the spleen. While most malaria 
episodes in endemic areas are uncomplicated, severe complications such as cerebral 
malaria or severe malarial anaemia occurs in a minority of cases (Greenwood et al., 
1991). Sequestration of IE at critical anatomical sites, such as the brain, appears to be 
involved in the pathogenesis of severe complications, such as cerebral malaria (Beeson 
and Brown, 2002). Each parasite has the ability to express a range of adhesins on the IE 
surface with specificity for a range of host receptors, presumably including brain-specific 
receptors, and can switch between expression of these adhesins by mechanisms that are 
currently being unravelled (Duraisingh et al., 2005; Freitas-Junior et al., 2005a,b).  
It thus appears that all parasites have the capacity to cause both uncomplicated and 
Severe Malaria (SM). We are now beginning to understand what determines which 
molecules are expressed on the IE surface and why only a minority of infections cause 
severe disease. 
3 Acquisition of protective immunity to P. falciparum malaria in areas 
with stable parasite transmission 
In areas with stable P. falciparum transmission, malaria mortality and severe morbidity is 
markedly concentrated among young children (typically those less than five years of age, 
but depending on endemicity). Older children continue to suffer clinical episodes, but 
little morbidity remains in adults. Nevertheless, most of the residents of such areas 
probably continue to have episodes of patent parasitemia throughout life. This is 
generally taken as evidence that protective immunity to malaria can be acquired in 
response to infection, but it also shows that the rate of acquisition is excruciatingly slow. 
Naturally acquired protective immunity appears to be mediated by IgG, as passive 
transfer of IgG from adults effectively controls parasitemia and symptoms in children 
with P. falciparum malaria (Cohen et al., 1961; Sabchareon et al., 1991). Furthermore, 
the passive transfer experiments point to the asexual blood stages of the infection as  
the most important target. Specifically, a rapidly growing body of evidence points to the 
above-mentioned parasite-encoded adhesins on the IE surface as the main antigenic 
target of protective IgG (Bull et al., 1998; Nielsen et al., 2002; Ofori et al., 2002), 
making them attractive vaccine candidates. A major obstacle, however, is the fact that 
they undergo clonal antigenic variation (and are therefore generally known as Variant 
Surface Antigens (VSA), and that the VSA repertoire of individual parasite clones is 
different, making the global VSA repertoire potentially vast. Thus, if the goal is to 
develop a vaccine that will prevent any parasitemia, this complication probably precludes 
VSA as vaccine targets. However, if the goal is vaccines that will protect from mortality 
and severe morbidity from well-defined clinical syndromes – and for us, it is – this 
problem may be much less serious for two reasons. 
Firstly, it has been repeatedly observed that, although sterile immunity is probably 
never achieved following exposure to P. falciparum parasites in endemic areas and 
acquisition of immunity to uncomplicated disease is slow, immunity to severe disease is 
acquired relatively quickly (Gupta et al., 1999). Pregnancy-Associated Malaria (PAM), 
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which is associated with severe mother/child morbidity, is a particularly striking example 
of rapid development of protective immunity to a particular P. falciparum malaria 
syndrome after very few – perhaps a single – episode (Brabin, 1983). 
Secondly, and very importantly, the pathogenesis of both PAM and SM in children 
have been associated with expression of particular VSA (VSAPAM and VSASM, 
respectively) with specific antigenic and functional properties (Beeson et al., 1999; Bull 
et al., 2000; Fried and Duffy, 1996; Nielsen et al., 2002; Ricke et al., 2000).  
VSA-specific immune responses appear to be the main factor determining which VSA 
will be expressed in a given infection, and therefore what the clinical consequences of it 
are likely to be. In the absence of specific immunity, parasites expressing virulent VSA 
(VSASM) seem at a competitive advantage (probably because they mediate particularly 
efficacious IE adhesion) over parasites expressing non-SM VSA. VSASM-expressing 
parasites will thus dominate infections in non-immune individuals, and such infections 
will tend to be severe. As VSASM-specific immunity is acquired, this advantage gradually 
disappears and infections will be dominated by parasites expressing less and less virulent 
VSA. Detailed discussions of the evidence are available elsewhere (Hviid, 2004; Hviid, 
2005; Hviid and Staalsoe, 2004). 
4 Identification of protective antigens 
The most rapid progress towards identifying VSA with potential as vaccine components 
has been related to studies of PAM. It illustrates well the power of advanced laboratory 
investigations guided by immuno-epidemiological field data (evidence-based vaccine 
research; Staalsoe et al., 2002). PAM constitutes an important exception to the general 
rule of malaria as a childhood disease in highly endemic areas, as previously protected 
women in such areas suddenly become susceptible to P. falciparum infection when 
becoming pregnant (McGregor and Smith, 1952). This susceptibility is very  
parity-dependent: while primigravidae are highly susceptible, women of high parity are 
largely protected (Brabin, 1983). From this type of evidence it became apparent that 
PAM is caused by parasites that do not thrive in non-pregnant hosts that and express 
antigens rapidly inducing protective immunity (McGregor, 1987). It is now firmly 
established that parasites causing PAM express particular VSA (VSAPAM) that are 
functionally and immunologically distinct from all other VSA (Fried and Duffy, 1996; 
Ricke et al., 2000). The fact that P. falciparum exposed men never possess  
VSAPAM-specific IgG (Beeson et al., 1999; Ricke et al., 2000) and the rapid clearance of 
pregnancy-associated parasitemia post partum (Nguyen-Dinh et al., 1988) are strong 
evidence that parasites expressing VSAPAM cannot survive in non-pregnant hosts. 
Importantly, protection from the main adverse clinical consequences of PAM 
(prematurity, maternal anaemia and low birth weight of offspring) is mediated by 
VSAPAM-specific IgG (Duffy and Fried, 2003; Staalsoe et al., 2004). Expression of 
VSAPAM can be induced in vitro by selection for IE adhesion to the placental receptor 
Chondroitin Sulphate A (CSA) (Ricke et al., 2000). We used this method to enforce 
VSAPAM expression in the P. falciparum line NF54 (Delemarre and Van der Kaay, 1979), 
which is the parental line of clone 3D7 (Walliker et al., 1987). The 3D7 clone has had its 
entire genome sequenced and annotated (Gardner et al. 2002), and we could thus design 
specific primers for each of the 3D7 var genes encoding the main VSA family, called 
PfEMP1, and analyse changes in transcription of each var gene in response to selection 
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for adhesion to CSA and acquisition of a VSAPAM phenotype (Salanti et al., 2003). By 
quantitative real-time PCR we could show that acquisition of VSAPAM expression was 
associated with markedly increased transcription of a single var gene, var2csa, and that 
this gene is preferentially transcribed by placental parasite isolates (Salanti et al., 2003; 
Tuikue-Ndam et al., 2005). Furthermore, the product of this gene, var2csa, is selectively 
expressed on the surface of VSAPAM-expressing parasites, and VAR2CSA-specific 
antibodies are associated with a decreased risk of delivering low birth weight babies 
(Salanti et al., 2004). Recently, studies of parasites where the var2csa gene has been 
knocked out have shown that such parasites loose their ability to adhere to CSA and to 
acquire the VSAPAM phenotype, lending further support for the central involvement of 
VAR2CSA in the pathogenesis of PAM (Viebig et al., 2005). Very recent data from our 
laboratory indicate that VAR2CSA is indeed the main target of naturally acquired 
protective immunity to PAM, and that human VAR2CSA-specific IgG can inhibit IE 
adhesion to CSA in vitro. These findings, and the fact that the structure of the VAR2CSA 
gene is both different from all other var genes (supporting the antigenic uniqueness of 
VAR2CSA) and conserved between genetically distinct isolates (Gardner et al., 2002; 
Salanti et al., 2003), have made VAR2CSA the current leading candidate for 
development of a PAM-specific vaccine (Smith and Deitsch, 2004). 
In a parallel approach, we are attempting to identify VSA that are associated with the 
pathogenesis of SM in children. Previous studies have shown that such VSA (VSASM) are 
serologically and functionally distinct from VSA associated with Uncomplicated Malaria 
(UM) (Bull et al., 2000; Nielsen et al., 2002). We have developed in vitro selection 
protocols to induce expression of VSASM (Staalsoe et al., 2003) and used such parasites to 
investigate which var genes are affected by selection for VSASM expression (Jensen et al., 
2004). These studies revealed that selection for VSASM expression is associated with 
preferential expression of a particular, structurally related subset of var genes that we 
have called Group A (Jensen et al., 2004; Kraemer and Smith, 2003; Lavstsen et al., 
2003). A major challenge immediately ahead will be an establishment of the receptor 
specificity of VSASM. This is likely to be more difficult than for VSAPAM since the 
pathogenesis of SM is multifactorial, and since multiple receptors are undoubtedly 
involved, even for individual types of VSA (Chen et al., 2000). 
5 Concluding remarks 
Complete, strain-transcending prevention of parasitemia and long-lasting (years to 
decades) protection are often cited as the main virtues of an ideal malaria vaccine.  
No such vaccine exists. We consider it questionable if ever it will. However, nature has 
shown that non-sterilising, long-lasting immunity protecting against mortality and severe 
morbidity can be developed. Maintenance of the protection afforded appears to require 
regular presence of low-grade parasitemia, and asymptomatic parasitemia has been 
shown to decrease the risk of subsequent clinical attacks (Ofori et al., 2002; Gaye et al., 
2005). Naturally acquired protection from malaria rests on VSA-specific IgG. 
Preservation of this immunity – and of immunity against particular VSA artificially 
induced by vaccination – thus appears to require repeated probing and boosting of  
VSA-specific immunity by the infecting parasites. This may render VSA-based vaccines 
inadequate for short-term visitors to endemic areas (e.g. tourists and military personnel). 
However, they would probably be acceptable – indeed, they may be preferable (because 
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of the likelihood of long-term protection) – to people with permanent residence in areas 
with stable parasite transmission. Such vaccines, designed specifically for developing 
countries, is our goal. 
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